

Annual General Meeting

NOVEMBER 2026

RAD

RADIOPHARM THERANOSTICS

Notice & Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN 647 877 889 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation is not a prospectus or other disclosure document under the *Corporations Act 2001* (Cth) and will not be lodged with the Australian Securities and Investments Commission. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this presentation (including electronically) outside Australia is restricted by law. If you come into possession of this presentation, you should observe such restrictions as any non-compliance with these restrictions could contravene applicable securities laws (see the section captioned ‘International offer restrictions’). In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The New Shares, Attaching Options and shares underlying the Attaching Options have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions registered under the US Securities Act or in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change.

RAD
RADIOPHARM THERANOSTICS

What Has Been Achieved to Date

RAD
RADIOPHARM THERANOSTICS



Phase 3 ready RAD101 (brain mets PET imaging)

Phase 2b primary endpoint met, 93% concordance with MRI (28/30 patients).One of only four Phase 3 imaging trials globally.



Phase 1 RAD301 (pancreatic PET imaging)

Positive Phase 1 read-out; FDA orphan drug designation. Albert Einstein NYC.



Phase 1 RAD204 PD-L1

Confirmed RECIST partial response at 90 mCi (43% tumor reduction, 9.5-month PFS); no DLTs in DL1–2.

RAD202

Phase 1 RAD202 Her-2

First three cohorts completed with no DLTs; 180 mCi cohort dosing; 1 of 5 DL3 patients with stable disease; 3 of 4 DL4 patients with stable disease.

RV01

Phase 1 RV01

First cohort completed in under 5 months; no DLT; Second cohort to be completed by Jan 2027. JV with MD Anderson Cancer Centre.

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center Making Cancer History®

RAD402

Phase 1 RAD402

First cohort completed, no DLT; 1 of 3 patients with stable disease, 6+ months on trial.



Global supply

Agreement with Siemens for RAD 101

SIEMENS

What's Next?


2026
H1 2027
H2 2027
Q4 2026
Q1 2027
Q2 2027
Q3 2027
Q4 2027
RAD 101Presentation/Poster at Society of Neuro-Oncology (SNO) in Philadelphia
RAD101 full sensitivity / specificity read-out; RAD101 and RAD301 partnering with upfront, milestones and royalties
RAD101 Phase 3 start (~280 patients; radiolabeling and distribution contracted with Siemens PETNET)
RAD202 and RAD204 dose-escalation completion
RV01 and RAD402 dose-escalation completion
Partnering discussions with 101 and 301
ONGOING

RAD

RADIOPHARM THERANOSTICS

www.radiopharmtheranostics.com

